Brukinsa (zanubrutinib) — Medica

Initial criteria

• Patient is age ≥ 18 years
• Patient meets ONE of the following: (i) tried at least one systemic regimen; OR (ii) not a candidate for a chemotherapy regimen; OR (iii) used in combination with rituximab; OR (iv) patient has TP53 mutation AND used as induction therapy in combination with Venclexta (venetoclax) and Gazyva (obinutuzumab)

Approval duration

1 year